That study, based on an older return calculation method that has since been widely replicated, highlighted the strong ...

But when a dividend yield reaches ultrahigh levels, investors can feel a heightened level of uncertainty. Wondering if Pfizer ...

Investors are closely monitoring the performance of Indian pharma companies in the March 2025 quarter and their ability to ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

Costs of product revenue were $0.4 million for the quarter ended March 31, 2025, compared to $0.5 million for the quarter ended March 31, 2024, partially due to obsolete inventory write offs of ...

Pfizer has received a “Moderate Buy” consensus from fifteen analysts, signaling cautious optimism rather than fanfare. One ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer Inc. closed 29.36% short of its 52-week high of $31.54, which the company reached on July 30th.

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.